

## Special Issue

# Progress in Influenza Vaccine Research

### Message from the Guest Editor

The impact of vaccines on the course of COVID-19 pandemic has brought to light the importance of vaccine research in pandemic preparedness. Current influenza vaccine will not be able to provide any protection in the case of influenza pandemic. Thus, there is a need for universal influenza vaccine that can induce broader and long lasting immune response to protect against all circulating and emerging influenza virus variants. To develop such a vaccine a deeper understanding of correlates of protection against influenza virus is required. In addition, improved vaccine production processes are also required to make enough vaccine doses quickly. We also need improved vaccines against avian and swine influenza virus to protect our livestock and to minimize chances of human exposure to these influenza viruses. Additionally, there is requirement for development of improved model systems for rapid testing and comparison of novel vaccines. Hopefully, we will be better prepared when a new influenza pandemic arrives. The special issue of Vaccines will cover all these aspects of influenza vaccine research. In this Special Issue, original research articles and reviews are welcome

### Guest Editor

Dr. Amit Gaba

Department of Biochemistry, Microbiology, and Immunology, College of Medicine, University of Saskatchewan, Saskatoon, SK, Canada

### Deadline for manuscript submissions

closed (31 July 2023)



## Vaccines

an Open Access Journal  
by MDPI

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/133014](https://mdpi.com/si/133014)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).